Target intelligence / Profile preview

Glutamate Receptors (NMDA, AMPA, Kainate, mGluR5) (NMDA (NMDAR), AMPA, Kainate (KAR), mGluR5)

Target
NMDA (NMDAR), AMPA, Kainate (KAR), mGluR5
Molecular classification
Ion channel, ligand-gated ionotropic glutamate receptor, G protein-coupled receptor (GPCR), metabotropic glutamate receptor
01

Overview

NMDA, AMPA, and kainate receptors are ionotropic glutamate receptors—ligand-gated ion channels—activated primarily by glutamate and differing in their subunit composition, pharmacological profiles, and physiological roles. They mediate fast excitatory neurotransmission and are crucial for synaptic plasticity, learning, and memory. The mGluR5 receptor is a metabotropic glutamate receptor (GPCR) modulating slower, second-messenger-driven neuronal responses. Each plays a distinct but overlapping role in central nervous system function, and all are therapeutic targets for various neurological and psychiatric conditions—including epilepsy, neurodegeneration, and pain syndromes. Note: This entry combines four molecular families; for structured databases, they should be split into individual canonical entities.

Other names
NMDARNR1/NR2/NR3 (subunit notation)GluA1-4GRIA1-4GluK1-5GRIK1-5GRM5
02

Mechanism of action

NMDA receptor antagonists block excitatory neurotransmission to prevent neurotoxicity; AMPA receptor antagonists inhibit fast synaptic transmission, used in seizure control; Kainate receptor antagonists modulate synaptic transmission and protect against neurotoxicity; mGluR5 antagonists inhibit G-protein-coupled signaling and modulate synaptic plasticity.

03

Biological functions

Synaptic transmissionSynaptic plasticityLearning and memorySignal transductionRegulation of neurotransmitter release
04

Disease associations

Neurodegenerative diseases (Alzheimer's, Huntington's)EpilepsyPsychiatric disorders (schizophrenia, depression, anxiety)Pain (including migraine)Ischemic brain injury
05

Safety considerations

Excitotoxicity with excessive inhibition/activationCognitive dysfunction, psychiatric side effects (hallucinations, dissociation — NMDA antagonists)Seizures, neurotoxicity (with ionotropic antagonists or agonists)Limited selectivity can lead to off-target effects
06

Interacting drugs

Memantine

13 more in the full profile.

07

Biomarkers

None universally established for NMDA, AMPA, Kainate, or mGluR5 receptor activation/inhibition; research uses subunit mRNA/protein levels or imaging ligands in select contexts

Beyond the preview

Go deeper on Glutamate Receptors (NMDA, AMPA, Kainate, mGluR5) (NMDA (NMDAR), AMPA, Kainate (KAR), mGluR5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate Receptors (NMDA, AMPA, Kainate, mGluR5) (NMDA (NMDAR), AMPA, Kainate (KAR), mGluR5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call